Results 71 to 80 of about 14,945 (175)

Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome

RMD Open, 2020
Objectives Several therapies are used for the treatment of rareautoinflammatory conditions like cryopyrin-associated periodic fever syndromes (CAPS), hyperimmunoglobulin Dsyndrome (HIDS)/mevalonate kinase deficiency (MKD) and tumour necrosis factor ...
Peter Hur, Syed Raza, Jasmin Beate Kuemmerle-Deschner, Raju Gautam, Aneesh Thomas George, Kathleen Graham Lomax   +5 more
doaj   +1 more source

Metabolic and crystal arthropathies: 112. Rapid Improvement in Health-Related Quality of Life in Gouty Arthritis Patients Treated with Canakinumab (ACZ885) Compared to Triamcinolone Acetonide [PDF]

, 2017
Background: Canakinumab, a fully human anti-IL-1β antibody has been shown to control inflammation in gouty arthritis. This study evaluated changes in health-related quality of life (HRQoL) in patients treated with canakinumab or triamcinolone acetonide ...
Arulmani, U., Arulmani, U., Balfour, A., Bodalia, B., De Meulemeester, M., De Meulemeester, M., Ferreira, A., Kerrane, J., Krammer, G., Lin, H., Murphy, V., Mysler, E., Nasonov, E., Pikhlak, A., Richard, D., Richard, D., Rovensky, J., Sallstig, P., Sallstig, P., Schlesinger, N., Schlesinger, N., So, Alexander, So, Alexander, Stricker, K., Yücel, A. E.   +24 more
core  

Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? [PDF]

, 2017
Data from basic science experiments is overwhelmingly supportive of the causal role of immune-inflammatory response(s) at the core of atherosclerosis, and therefore the theoretical potential to manipulate the inflammatory response to prevent ...
Abbas, Agca, Ait-Oufella, Albert, Alexander, Alexander, Alexander, Alexander, Andersen, Aziz, Babelova, Bellosta, Bevilacqua, Bhaskar, Blom, Boekholdt, Boekholdt, Bostrom, Brånén, Bulgarelli, Bulgarelli, Burke, Cai, Cannon, Casas, Collins, Cronstein, Dahlman-Ghozlan, Danesh, Davenport, Davey Smith, Davidson, DeOliveira, Devlin, Dinarello, Duewell, Duivenvoorden, Eisenhardt, Elango, Elhage, Ettehad, Flood, Fraser, Freigang, Fulgoni, Galkina, Galkina, Garlanda, Grassia, Grassia, Greenberg, Hansson, Hauer, Herder, Holmes, Hu, Huang, Huber, Interleukin 1 Genetics Consortium, Ivandic, Kalliolias, Kaptoge, Kimura, Kinlay, Kirii, Kleinman, Koltsova, Kureishi, Kwak, Lee, Leite, Leite, Lewington, Liao, Libby, Libby, Macritchie, Maddaluno, Maeda, Maffia, Makheja, Margaritis, McInnes, Menu, Micha, Mihaylova, Mira, Mohler, Montezano, Mulhaupt, Murad, Myasoedova, Myung, Nakata, Nicholls, O'Donoghue, Ogdie, Ohta, Pauling, Peters, Qiao, Quarck, Rajamäki, Rastogi, Reiss, Rezaie-Majd, Ridker, Ridker, Rincón, Robertson, Romano, Rosenson, Rosenson, Roubille, Ryan, Rössig, Saeed, Sage, Sarwar, Sattar, Scalia, Schett, Schieffer, Schuett, Serruys, Sever, Sever, Shah, Shaposhnik, Singh, Sirtori, Sniderman, Soedamah-Muthu, Solomon, Southan, Souverein, Sprague, Srikakulapu, Strober, Sukovich, Swerdlow, Swirski, Talmud, Tay, Teng, Thompson, Tits, Toedter, Turunen, Tzellos, Walker, Wang, Wang, Watson, Weintraub, Welsh, Welsh, Welsh, Welsh, Weng, Wensley, White, Wilensky, Willeit, Willis, Wong, Woodward, Xanthoulea, Ye, Ye, Yilmaz, Youssef, Zalewski, Zhao   +173 more
core   +2 more sources

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

Canakinumab in the treatment of systemic juvenile idiopathic arthritis: a retrospective single center study in China

Frontiers in Pediatrics
ObjectiveSystemic juvenile idiopathic arthritis (sJIA) is characterized by excessive production of proinflammatory cytokines. As an anti-IL-1 agent, canakinumab has been approved in the USA and Europe for the treatment of sJIA patients aged ≥2 years ...
Xiaona Zhu, Ruohang Weng, Yanyan Huang, Yongbin Xu, Jun Yang, Tingyan He   +5 more
doaj   +1 more source

Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome [PDF]

, 2017
OBJECTIVE: To explore whether gene expression profiling can identify a molecular mechanism for the clinical benefit of canakinumab treatment in patents with tumour necrosis factor receptor-associated periodic syndrome (TRAPS). METHODS: Blood samples were
Abrams, K, Caorsi, R, Cattalini, M, Gattorno, M, Hartmann, N, Lachmann, H, Letzkus, M, Nirmala, N, Obici, L, Starck-Schwertz, S, Torene, R, Tormey, V   +11 more
core  

The journey of canakinumab; on- and off-label indications [PDF]

Beyond Rheumatology, 2019
The role of interleukin-1 (IL-1) has been studied in many diseases, ranging from auto-inflammatory diseases to malignancies, and much has been discovered.
Daniela Marotto, Alberto Batticciotto, Angela Ceribelli, Piercarlo Sarzi Puttini   +3 more
doaj   +1 more source

Concurrent Oral 1 - Therapy of rheumatic disease: OP4. Effectiveness of Rituximab in Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register (BSRBR) [PDF]

, 2017
Background: Rituximab (RTX) in combination with methotrexate (MTX) has been licensed since 2006 for the management of severe active rheumatoid arthritis (RA) in patients who have failed at least one anti-tumour necrosis factor (anti-TNF) therapy ...
's Vernon, Emma, Arulmani, U., Ashcroft, Darren M., Bodalia, B., Cartwright, R., Chakravarty, Kuntal, Choy, Ernest, Christidis, Dimitrios, Cooper, Robert G., Danko, Katalin, Dasgupta, Bhaskar, De Meulemeester, M., Foeldvari, I., Gattorno, M., Genovese, Mark C., Gordon, Patrick, Griffiths, Bridget, Hachulla, E., Hakim, Alan, Hassan, Nada, Hawkins, P. N., Hoyer, J., Hyrich, Kimme L., Ibrahim, Fowzia, Incera, E., Isenberg, David, Kerrane, J., Kitas, George, Kone-Paut, I., Kowalczyk, Anna, Krammer, G., Kuemmerle-Deschner, J. B., Lachmann, H. J., Lecky, Bryan, Lepore, L., Leslie, K., Lunt, Mark, Mapplebeck, Sarah, Murphy, V., Pikhlak, A., Preiss, R., Quartier, P., Ramos, E., Richard, D., Rubbert-Roth, Andrea, Sallstig, P., Scali, Juan, Schlesinger, N., Scott, David L., Sebba, Anthony, So, Alexander, Soliman, Moetaza M., Symmons, Deborah, Vollenhoven, Ronald, Watson, Kath D., Weisbarth-Riedel, E., White-Alao, Beverley, Winer, John, Yücel, A. E., Zilberstein, Moshe, Zulian, F.   +60 more
core  

Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern. The fragile balance between infections and autoimmunity [PDF]

, 2020
On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency.
Diamanti, A. P., Lagana, B., Pioli, C., Rosado, M. M., Sesti, G.   +4 more
core   +2 more sources

The Role of NLRP1, AIM2 and MEFV Inflammasomes in the High‐Intensity Interval Training of Individuals With Obesity

Immunology, EarlyView.
This study shows that 8 weeks of high‐intensity interval training (HIIT) modulate inflammasome‐related gene expression in individuals with obesity. HIIT increased AIM2, MEFV, CARD16 and CARD18 expression, with CARD16 upregulation supporting reduced inflammation through inhibition of caspase‐1 activation and lower IL‐1β levels.
Ana Luíza Pereira Assunção Silveira, Daniela Alves de Abreu, Amanda de Lima Santos Musto, Luiz Henrique da Silva Nali, Jônatas Bussador do Amaral, André Luis Lacerda Bachi, Marina Tiemi Shio, Paula Rezende‐Teixeira, Carolina Nunes França   +8 more
wiley   +1 more source